Carisma Therapeutics Inc.
Carisma Therapeutics Inc. (CARM): 5 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.7 months
0% dilution
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for Carisma Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$891K
Cash
$2.8M
Quarterly Burn
$1.4M
Runway
7.7 mo
Revenue
$45.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| CT-0508 | Phase 1 |
| CT-0525 | Phase 1 |
| CT-1119 | Phase 1 |
| CT-2401 | Preclinical |
| Moderna development candidate - GPC3 | Preclinical |
Frequently asked questions
How many drug candidates are in Carisma Therapeutics Inc.'s pipeline?
Carisma Therapeutics Inc. (CARM) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Carisma Therapeutics Inc.'s lead drug candidate?
Carisma Therapeutics Inc.'s most advanced tracked candidate is CT-0508 (Phase 1) for HER2-expressing cancers / solid tumors (HER2 program).
What is Carisma Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Carisma Therapeutics Inc. has approximately 7.7 months of cash runway.
What is Carisma Therapeutics Inc.'s market capitalization?
Carisma Therapeutics Inc.'s market capitalization is approximately $891K.
Who is the CEO of Carisma Therapeutics Inc.?
Chief Executive Officer is the chief executive officer of Carisma Therapeutics Inc. (CARM).
Get the full picture on Carisma Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.